Clinical practice drives marimastat deal

Clinical practice drives marimastat deal

In a move to secure a position in Japan's market for cancer drugs, Tanabe Seiyaku Co. Ltd. (Osaka, Japan) sealed a deal potentially worth $74 million to develop and market British Biotech plc's marimastat

Read the full 392 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE